Compare prices and buy Epitalon from 37 research peptide vendors - also called suppliers or sources. Updated daily.
A synthetic tetrapeptide (Ala-Glu-Asp-Gly / AEDG, CAS 307297-39-8) developed by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology as a synthetic analog of epithalamin, a bovine pineal-gland extract. Reported in cell studies to induce telomerase activity and telomere elongation, and in aged-animal studies from its developers to affect melatonin and other pineal-hypothalamic hormone rhythms. Not FDA-approved.
For research purposes only. Not medical advice.
Epitalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, usually written AEDG. It was designed as a defined-structure analog of epithalamin, a peptide preparation extracted from bovine pineal gland, by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology.
The claim it is sold on is telomerase activation. A 2003 report in Bulletin of Experimental Biology and Medicine from Khavinson's group described the peptide inducing telomerase activity and telomere elongation in cultured human fetal fibroblasts, and a 2004 follow-up from the same group reported treated cells dividing past the point where the cultures normally arrest. Related work from the same program reports normalization of melatonin secretion rhythms and pineal-hypothalamic hormone output in aged animals, and antioxidant effects. Its mouse lifespan studies are mixed: a 2001 study reported longer life with fewer spontaneous tumors, while a 2003 study in another strain found mean lifespan and total tumor incidence unchanged, with a longer maximum lifespan.
Underneath those results sits a broader hypothesis: that ultra-short peptides of two to four residues enter the nucleus, bind DNA in a sequence-selective way, and modulate expression of genes in one specific target tissue, which in Epitalon's case is the pineal gland. That model is the organizing idea behind the whole Khavinson bioregulator class, which also includes Pinealon and Thymalin in this catalogue. It is a mechanistic hypothesis promoted principally by one research program, not an independently established mechanism.
The Epitalon literature is concentrated almost entirely in one institute, published largely in Russian-language journals, built on small sample sizes, and rarely replicated by independent laboratories. In 2025 an independent laboratory at Brunel University London reported the same direction of effect in cell culture, with telomerase upregulation and longer telomeres in two normal human cell lines. The observation is about how much weight the published record can carry. It makes no judgment on whether the work is correct.
Several of the long-running clinical observations cited for Epitalon (multi-year follow-ups in elderly subjects reported by the same institute) were conducted with epithalamin, the pineal extract, rather than with the synthetic tetrapeptide. The two are related by design but are not the same substance: one is a defined four-residue peptide, the other a mixture. Evidence generated with the extract does not automatically transfer to the peptide.
ClinicalTrials.gov lists no registered study of Epitalon as of October 2026, and it is not approved by the FDA for any indication.
Epitalon's status inside the US compounding system has moved twice in three years:
One detail of that vote is worth pausing on. The only use FDA evaluated was insomnia. The nominations also proposed anti-aging, longevity and telomere lengthening, but FDA did not evaluate those uses because the nominations lacked the information it needed. The committee evaluated Epitalon as a sleep drug. FDA's briefing found no studies of Epitalon in patients with insomnia and no human safety data, and noted that its reported telomerase activation gives it a mechanistic potential to be carcinogenic that the available mouse studies were too limited to assess.
The recommendation is non-binding: the 503A list changes only through notice-and-comment rulemaking, and as of October 2026 the Federal Register carries no proposed rule naming Epitalon. Our writeup of the July 2026 PCAC vote covers all seven substances, including DSIP. None of it changes the status of research-grade Epitalon sold by peptide vendors, which is offered for laboratory use only and not for human consumption.
Epitalon is sold under several spellings and one genuinely misleading alias.
PeptideScouter indexes Epitalon per milligram and verifies identity against its molecular formula (C14H22N4O9, CAS 307297-39-8).
No. Epitalon is not approved by the FDA for any indication and ClinicalTrials.gov lists no registered study of it. On July 24, 2026 the Pharmacy Compounding Advisory Committee voted 7-5 with one abstention to recommend adding it to the 503A bulk drug substances list, over the objection of FDA's own review staff. That vote is advisory and the list changes only through notice-and-comment rulemaking. In October 2026 HHS said it does not intend to take enforcement action against pharmacies and physicians compounding Epitalon acetate under set conditions until a final rule decides the listing. Material sold by research vendors is for laboratory use only and not for human consumption.
Insomnia. The nominations also proposed anti-aging, longevity and telomere lengthening, but FDA evaluated only insomnia because the nominations lacked the information needed to assess the other uses, and the Pharmacy Compounding Advisory Committee voted in July 2026 on that basis. FDA's briefing found no studies of Epitalon in patients with insomnia.
No, though the names are sometimes used interchangeably, including in the compounding nominations FDA reviewed in 2026, and FDA treats them as different substances. Epithalamin, a peptide preparation extracted from bovine pineal gland, is a mixture. Epitalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, designed as a defined-structure analog of it. Several of the long-running clinical observations cited for Epitalon were actually conducted with the extract rather than the synthetic peptide, so it is worth checking which substance a cited study used.
Partly. The original report came from Vladimir Khavinson's group at the Saint Petersburg Institute of Bioregulation and Gerontology in 2003, describing telomerase induction and telomere elongation in cultured human fetal fibroblasts. In 2025 an independent laboratory at Brunel University London reported telomerase upregulation and longer telomeres in two normal human cell lines, also in cell culture. Most other work on the compound comes from the same institute, is published largely in Russian-language journals, and uses small sample sizes.
Epitalon is sold by 37 research peptide vendors indexed on PeptideScouter, with 70 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
36 of the 37 indexed vendors currently have Epitalon in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Northline Labs currently lists Epitalon at $0.75/mg, the lowest listed price across 37 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $0.67/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 37 vendors listing Epitalon publish a PeptideScouter code, worth 5% to 50% off. Applied, the lowest effective price falls from $0.75/mg listed to $0.67/mg at Northline Labs. Each vendor's code is shown beside its price in the table above.
Epitalon ranges from $0.75/mg to $9.20/mg across 70 listings from 37 research peptide vendors, normalized to USD per milligram and refreshed daily.
37 research peptide vendors currently list Epitalon on PeptideScouter, with 36 in stock right now. We track 70 listings across size and kit variants.
Epitalon's CAS Registry Number is 307297-39-8. It is also sold as Epithalon, EPITHALON, AEDG.
